Dual mechanisms for the regulation of brain-derived neurotrophic factor by valproic acid in neural progenitor cells

다국어 초록 (Multilingual Abstract)

Autism spectrum disorders (ASDs) are neurodevelopmental disorders that share behavioral features, the results of numerous studies have suggested that the underlying causes of ASDs are multifactorial. Behavioral and/or neurobiological analyses of ASDs have been performed extensively using a valid model of prenatal exposure to valproic acid (VPA). Abnormal synapse formation resulting from altered neurite outgrowth in neural progenitor cells (NPCs) during embryonic brain development has been observed in both the VPA model and ASD subjects. Although several mechanisms have been suggested, the actual mechanism underlying enhanced neurite outgrowth remains unclear. In this study, we found that VPA enhanced the expression of brain-derived neurotrophic factor (BDNF), particularly mature BDNF (mBDNF), through dual mechanisms. VPA increased the mRNA and protein expression of BDNF by suppressing the nuclear expression of methyl-CpG-binding protein 2 (MeCP2), which is a transcriptional repressor of BDNF. In addition, VPA promoted the expression and activity of the tissue plasminogen activator (tPA), which induces BDNF maturation through proteolytic cleavage. Trichostatin A and sodium butyrate also enhanced tPA activity, but tPA activity was not induced by valpromide, which is a VPA analog that does not induce histone acetylation, indicating that histone acetylation activity was required for tPA regulation. VPA-mediated regulation of BDNF, MeCP2, and tPA was not observed in astrocytes or neurons. Therefore, these results suggested that VPA-induced mBDNF upregulation was associated with the dysregulation of MeCP2 and tPA in developing cortical NPCs.

참고문헌 (Reference)

1 Lee SH, "tPA regulates neurite outgrowth by phosphorylation of LRP5/6 in neural progenitor cells" 49 : 199-215, 2014

2 Lu L, "c-Jun amino-terminal kinase is involved in valproic acid-mediated neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons" 42 : 1254-1266, 2017

3 Larsson P, "Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse" 14 : 2496-2508, 2016

4 Oikawa H, "Valproic acid mediates miR-124 to down-regulate a novel protein target, GNAI1" 91 : 62-71, 2015

5 Cho KS, "Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity" 61 : 694-709, 2013

6 Chen PS, "Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes" 11 : 1116-1125, 2006

7 Olesen JB, "Valproate attenuates the risk of myocardial infarction in patients with epilepsy : a nationwide cohort study" 20 : 146-153, 2011

8 Good KV, "Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity" 12 : 934-944, 2017

9 Pan W, "Transport of brain-derived neurotrophic factor across the blood-brain barrier" 37 : 1553-1561, 1998

10 Gravanis I, "Tissue plasminogen activator and glial function" 49 : 177-183, 2005

11 Chen SL, "Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder" 24 : 1753-1759, 2014

12 Yasuda S, "The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons" 14 : 51-59, 2009

13 Strahl BD, "The language of covalent histone modifications" 403 : 41-45, 2000

14 Chang Q, "The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression" 49 : 341-348, 2006

15 State MW, "The conundrums of understanding genetic risks for autism spectrum disorders" 14 : 1499-1506, 2011

16 Wei R, "Strain-specific BDNF expression of rat primary astrocytes" 220 : 90-98, 2010

17 Arts J, "Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation" 310 : 171-176, 1995

18 Zhang Y, "Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex" 277 : 33431-33438, 2002

19 Miyazaki K, "Serum neurotrophin concentrations in autism and mental retardation: a pilot study" 26 : 292-295, 2004

20 Hellweg R, "Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment" 41 : 66-71, 2008

21 Sen S, "Serum brain-derived neurotrophic factor, depression, and antidepressant medications : meta-analyses and implications" 64 : 527-532, 2008

22 Cunha AB, "Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes" 398 : 215-219, 2006

23 Persico AM, "Searching for ways out of the autism maze : genetic, epigenetic and environmental clues" 29 : 349-358, 2006

24 Larsson P, "Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression" 7 : e31573-, 2012

25 Hara Y, "Prenatal exposure to valproic acid increases miR-132 levels in the mouse embryonic brain" 8 : 33-, 2017

26 Karege F, "Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets" 328 : 261-264, 2002

27 Piccinni A, "Plasma and serum brain-derived neurotrophic factor(BDNF)in depressed patients during 1 year of antidepressant treatments" 105 : 279-283, 2008

28 Zheng Z, "Peripheral brainderived neurotrophic factor in autism spectrum disorder : a systematic review and meta-analysis" 6 : 31241-, 2016

29 Esteller M., "Non-coding RNAs in human disease" 12 : 861-874, 2011

30 Hastings GA, "Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival" 272 : 33062-33067, 1997

31 Harrison IF, "Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson’s is associated with histone acetylation and upregulation of neurotrophic factors" 172 : 4200-4215, 2015

32 Nelson KB, "Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation" 49 : 597-606, 2001

33 Ben-Ari Y, "Neuro-archaeology : pre-symptomatic architecture and signature of neurological disorders" 31 : 626-636, 2008

34 Maisonpierre PC, "NT-3, BDNF, and NGF in the developing rat nervous system : parallel as well as reciprocal patterns of expression" 5 : 501-509, 1990

35 Klose R, "Molecular biology. MeCP2 repression goes nonglobal" 302 : 793-795, 2003

36 Volvert ML, "MicroRNAs tune cerebral cortical neurogenesis" 19 : 1573-1581, 2012

37 Im HI, "MicroRNAs in neuronal function and dysfunction" 35 : 325-334, 2012

38 Sun AX, "MicroRNAs : regulators of neuronal fate" 25 : 215-221, 2013

39 Geaghan M, "MicroRNA and posttranscriptional dysregulation in psychiatry" 78 : 231-239, 2015

40 Chahrour M, "MeCP2, a key contributor to neurological disease, activates and represses transcription" 320 : 1224-1229, 2008

41 Nguyen MV, "MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain" 32 : 10021-10034, 2012

42 Im HI, "MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212" 13 : 1120-1127, 2010

43 Dregan A, "Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study" 23 : 759-767, 2014

44 Tsai SJ, "Is autism caused by early hyperactivity of brain-derived neurotrophic factor?" 65 : 79-82, 2005

45 Correia CT, "Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism" 9 : 841-848, 2010

46 Almeida LE, "Increased BDNF expression in fetal brain in the valproic acid model of autism" 59 : 57-62, 2014

47 Roullet FI, "In utero exposure to valproic acid and autism--a current review of clinical and animal studies" 36 : 47-56, 2013

48 Mandel AL, "Identification of pro-and mature brain-derived neurotrophic factor in human saliva" 54 : 689-695, 2009

49 Klein ME, "Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA" 10 : 1513-1514, 2007

50 Bredy TW, "Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear" 14 : 268-276, 2007

51 Phiel CJ, "Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen" 276 : 36734-36741, 2001

52 Wu X, "Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons" 11 : 1123-1134, 2008

53 Kim S, "Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites" 342 : 1168-1173, 2006

54 Sowa Y, "Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites" 241 : 142-150, 1997

55 Lee JH, "Histone deacetylase activity is required for embryonic stem cell differentiation" 38 : 32-38, 2004

56 Murgatroyd C, "Genes learn from stress : how infantile trauma programs us for depression" 5 : 194-199, 2010

57 Calfa G, "Experimental models of Rett syndrome based on Mecp2 dysfunction" 236 : 3-19, 2011

58 Boulle F, "Epigenetic regulation of the BDNF gene: implications for psychiatric disorders" 17 : 584-596, 2012

59 Dunoyer-Geindre S, "Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells" 90 : 457-463, 2011

60 Schneider T, "Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid : issues for a therapeutic approach in autism" 31 : 36-46, 2006

61 Yoshimura R, "Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients" 31 : 1034-1037, 2007

62 Park SW, "Effects of mood-stabilizing drugs on dendritic outgrowth and synaptic protein levels in primary hippocampal neurons" 17 : 278-290, 2015

63 Croce N, "Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration" 28 : 964-972, 2014

64 Hasan MR, "Effect of HDAC inhibitors on neuroprotection and neurite outgrowth in primary rat cortical neurons following ischemic insult" 38 : 1921-1934, 2013

65 Nishino S, "Divergent effects of lithium and sodium valproate on brain-derived neurotrophic factor(BDNF)production in human astrocytoma cells at therapeutic concentrations" 39 : 17-22, 2012

66 Martinowich K, "DNA methylation-related chromatin remodeling in activitydependent BDNF gene regulation" 302 : 890-893, 2003

67 Klose RJ, "DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to methyl-CpG" 19 : 667-678, 2005

68 Gao R, "Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders" 15 : 146-167, 2015

69 Dias VV, "Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder" 11 : 663-671, 2009

70 Pang PT, "Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity" 306 : 487-491, 2004

71 Rasalam AD, "Characteristics of fetal anticonvulsant syndrome associated autistic disorder" 47 : 551-555, 2005

72 조봉기, "Changes in the Histone Acetylation Patterns during the Development of the Nervous System" 한국뇌신경과학회 20 (20): 81-84, 2011

73 Arts J, "Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro" 25 : 311-317, 1997

74 Girdhar K, "Cell-specific histone modification maps in the human frontal lobe link schizophrenia risk to the neuronal epigenome" 21 : 1126-1136, 2018

75 Kooistra T, "Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells" 247 : 605-612, 1987

76 Connolly AM, "Brainderived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy" 59 : 354-363, 2006

77 Fukumitsu H, "Brain-derived neurotrophic factor participates in determination of neuronal laminar fate in the developing mouse cerebral cortex" 26 : 13218-13230, 2006

78 Murer MG, "Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease" 63 : 71-124, 2001

79 Klein AB, "Blood BDNF concentrations reflect brain-tissue BDNF levels across species" 14 : 347-353, 2011

80 Li W, "Beyond widespread Mecp2 deletions to model rett syndrome : conditional spatio-temporal knockout, single-point mutations and transgenic rescue mice" 2012 : 5-, 2012

81 Roullet FI, "Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid" 170 : 514-522, 2010

82 Schneider T, "Behavioral alterations in rats prenatally exposed to valproic acid : animal model of autism" 30 : 80-89, 2005

83 Larimore JL, "Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations" 34 : 199-211, 2009

84 Li W, "BDNF deregulation in Rett syndrome" 76 (76): 737-746, 2014

85 Geschwind DH, "Autism spectrum disorders : developmental disconnection syndromes" 17 : 103-111, 2007

86 Berg JM, "Autism genetics : searching for specificity and convergence" 13 : 247-, 2012

87 Eadie MJ, "Antiepileptic drugs as human teratogens" 7 : 195-209, 2008

88 Garcia KL, "Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism" 71 : 289-297, 2012

89 Shimizu E, "Alterations of serum levels of brain-derived neurotrophic factor(BDNF)in depressed patients with or without antidepressants" 54 : 70-75, 2003

90 Medcalf RL, "A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP" 265 : 14618-14626, 1990